DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests an experimental treatment called QEL-005 in 16 adults with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetical…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated May 17, 2026 04:14 UTC
-
New drug shows promise for rare scleroderma in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called ianalumab in 200 adults with a severe form of scleroderma that affects the skin and internal organs. Participants receive either the drug or a placebo to see if it improves disease activity and lung function over 52 weeks. The goal is to find a …
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New hope for rare scleroderma: experimental drug MTX-474 enters phase 2 trial
Disease control Recruiting nowThis study tests whether the experimental drug MTX-474 can safely reduce skin thickening in people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin to harden and can damage internal organs. About 85 adults with early-stage disease will receive…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:10 UTC
-
Engineered cells take aim at tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new treatment called CTX112 for people with severe autoimmune diseases like lupus, scleroderma, or myositis that haven't improved with standard therapies. CTX112 uses specially engineered immune cells from a donor to target and attack faulty immune …
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug trial aims to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find the safest and most effective dose by checking side effects and how the drug works in the body. Participants will be followed for about 13 months, and …
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 04, 2026 16:24 UTC